EVH Evolent Health (EVH) Insider Trading, Ownership & Congress Trades
Services · Services-management services · CIK 0001628908
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
105
13F, latest reported quarter
What the filings say about EVH
Insiders, 180 days
-$329.5K net sold
1 seller · 100% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$327.5K
1 notice
Evolent Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Evolent Health, Inc. insiders sold a net $329.5K of stock across 104 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 8 earlier Form 4 trades (code P or S) here by this insider (1 buy, 7 sales), the last on Mar 6, 2025.
- The trade is 10.1% of the 655,133 shares held after it.
- No other insider sold within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT McCarthy Daniel Joseph sold about $329.5K of EVH under a 10b5-1 plan on Aug 26, 2026, the largest insider sale at the company since 2024; 105 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Mar 7, 2025.
- -10.2% median (-10.2% mean) 90-day return after 2 previous buys.
- The trade is 17.0% of the 58,821 shares held after it.
- No other insider bought within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Springstubb Brendan B bought about $38.2K of EVH on Nov 18, 2025; 105 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 15,000 shares held after it.
- 8 other insiders bought within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jelinek Richard M bought about $136.3K of EVH on Mar 7, 2025; 8 other insiders bought within 30 days and 105 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 15,000 shares held after it.
- 8 other insiders bought within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jelinek Richard M bought about $137.4K of EVH on Mar 7, 2025; 8 other insiders bought within 30 days and 105 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 4, 2025.
- The trade is 55.9% of the 26,842 shares held after it.
- 8 other insiders bought within 30 days.
- 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Springstubb Brendan B bought about $139.1K of EVH on Mar 7, 2025; 8 other insiders bought within 30 days and 105 funds added in the latest 13F quarter.104 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$329.5K over 180 days
-$329.5K over 90 days
more than 53% of Services
Congress
no House purchase disclosed in the last 12 months
Funds
105 funds bought in last quarter
more than 53% of Services
Revenue
-26.6% year over year
below 90% of Services
Margin
-28.5% net margin
below 83% of Services
Buybacks
$40.0M repurchased, FY to 2025-12-31
below 52% of Services
Short interest
13.7% of the float short (float per yahoo 2026-10-26) · 5.5 days to cover · settled 2026-09-30
more than 90% of Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch EVH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-40.6%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns EVH: institutional holders (13F)
13F holdings, latest reported quarter
14,814,851 sh
$80.3M
10,814,473 sh
$58.6M
8,969,012 sh
$48.6M
6,245,283 sh
$33.8M
5,816,123 sh
$31.5M
Congress trades in EVH
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
EVH planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Daniel McCarthy
Filed 2026-08-26
$327.5K
EVH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Arena Strategic Income Fund
$313.1K position · as of 2026-07-31
0.7%
NORTH SQUARE KENNEDY MICROCAP FUND
$200.6K position · as of 2026-05-31
0.6%
Ultra-Small Company Market Fund
$813.0K position · as of 2026-06-30
0.5%
NVIT Small Cap Value Fund
$811.6K position · as of 2026-06-30
0.4%
ABSOLUTE CONVERTIBLE ARBITRAGE FUND
$6.0M position · as of 2026-06-30
0.3%
Janus Henderson Small Cap Growth Alpha ETF
$1.1M position · as of 2026-07-31
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Seth Blackley
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$14.2M
$2.6M
$5.0M
-75%
-1%
2024
$11.1M
-$9.3M
$4.1M
-30%
-19%
2023
$8.9M
$20.1M
$3.2M
+106%
-18%
2022
$7.7M
$11.8M
$2.5M
+75%
-23%
2021
$6.5M
$21.9M
$1.6M
+73%
-4%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $329.5K sold by insiders over 180 days, 105 funds added last quarter, $327.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
EVH financials
Revenue growth
-26.6%
XBRL, annual
Net margin
-28.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM EVH
| FY Dec 2025 | $1.9B |
| FY Dec 2024 | $2.6B |
| FY Dec 2023 | $2.0B |
| FY Dec 2022 | $1.4B |
| FY Dec 2021 | $908.0M |
| Jun 2026 | $652.5M |
| Mar 2026 | $496.2M |
| Dec 2025 | $468.7M |
| Sep 2025 | $479.5M |
| Jun 2025 | $444.3M |
| Mar 2025 | $483.6M |
| Dec 2024 | $646.5M |
| Sep 2024 | $621.4M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM EVH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1.4% |
| FY Dec 2021 | -4.1% |
| Jun 2026 | -4.3% |
| Mar 2026 | -5.4% |
| Dec 2025 | -91.6% |
| Sep 2025 | -4.4% |
| Jun 2025 | -4.5% |
| Mar 2025 | -13.4% |
| Dec 2024 | -3.5% |
| Sep 2024 | -3.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$24.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM EVH
| FY Dec 2025 | $4.8M |
| FY Dec 2024 | -$6.1M |
| FY Dec 2023 | $113.8M |
| FY Dec 2022 | -$49.9M |
| FY Dec 2021 | $13.8M |
| Jun 2026 | -$16.2M |
| Mar 2026 | -$7.4M |
| Dec 2025 | $41.0M |
| Sep 2025 | $6.8M |
| Jun 2025 | -$39.1M |
| Mar 2025 | -$4.0M |
| Dec 2024 | -$32.4M |
| Sep 2024 | $12.4M |
At each fiscal year end
Single quarter
Debt to equity
2.52x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity EVH
| FY Dec 2025 | 2.34x |
| FY Dec 2024 | 0.66x |
| FY Dec 2023 | 0.56x |
| FY Dec 2022 | 0.48x |
| FY Dec 2021 | 0.31x |
| Jun 2026 | 2.52x |
| Mar 2026 | 2.46x |
| Dec 2025 | 2.34x |
| Sep 2025 | 1.26x |
| Jun 2025 | 0.92x |
| Mar 2025 | 0.88x |
| Dec 2024 | 0.66x |
| Sep 2024 | 0.58x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.06x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Cash flow to debt EVH
| FY Dec 2025 | 0.04x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | 0.24x |
| FY Dec 2022 | -0.03x |
| FY Dec 2021 | 0.18x |
| Jun 2026 | 0.06x |
| Mar 2026 | 0.03x |
| Dec 2025 | 0.04x |
| Sep 2025 | -0.03x |
| Jun 2025 | -0.04x |
| Mar 2025 | 0.02x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on equity EVH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -2.5% |
| FY Dec 2021 | -5.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on assets EVH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1.2% |
| FY Dec 2021 | -2.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital EVH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-25.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed EVH
| FY Dec 2025 | -24.5% |
| FY Dec 2024 | -2.1% |
| FY Dec 2023 | -4.2% |
| FY Dec 2022 | +0.3% |
| FY Dec 2021 | -4.4% |
| Jun 2026 | -25.3% |
| Mar 2026 | -24.6% |
| Dec 2025 | -24.5% |
| Sep 2025 | -1.0% |
| Jun 2025 | -1.9% |
| Mar 2025 | -1.5% |
| Dec 2024 | -2.1% |
| Sep 2024 | -2.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing EVH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.4B
market value at close 2026-10-23 on 2026-08-01 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value EVH
| FY Dec 2025 | $1.3B |
| FY Dec 2024 | $1.9B |
| FY Dec 2023 | $4.2B |
| FY Dec 2022 | $3.1B |
| FY Dec 2021 | $2.4B |
| Jun 2026 | $1.5B |
| Mar 2026 | $1.1B |
| Dec 2025 | $1.3B |
| Sep 2025 | $1.9B |
| Jun 2025 | $2.0B |
| Mar 2025 | $1.7B |
| Dec 2024 | $1.9B |
| Sep 2024 | $3.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.5%
TTM free cash flow over market value at close 2026-10-23
FCF yield EVH
| FY Dec 2025 | +1.1% |
| FY Dec 2024 | -0.5% |
| FY Dec 2023 | +3.0% |
| FY Dec 2022 | -1.8% |
| FY Dec 2021 | +0.6% |
| Jun 2026 | +4.0% |
| Mar 2026 | +0.5% |
| Dec 2025 | +1.1% |
| Sep 2025 | -6.9% |
| Jun 2025 | -4.8% |
| Mar 2025 | -0.9% |
| Dec 2024 | -0.5% |
| Sep 2024 | +3.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing EVH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.9B | $2.6B | $2.0B | $1.4B |
| Operating income | -$410.1M | -$40.5M | -$71.2M | $3.6M |
| Net income | -$579.4M | -$93.5M | -$142.3M | -$19.2M |
| EPS (diluted) | -5.07 | -0.81 | -1.28 | -0.20 |
| Operating cash flow | $38.8M | $18.8M | $142.6M | -$11.6M |
| Cash | $151.9M | $104.2M | $192.8M | $188.2M |
| Long-term debt | $970.5M | $490.5M | $597.0M | $413.0M |
| Buybacks | $40.0M | $0 | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-27
EVH Stock Sonar score 5/7 axes
Find similar shapesCompareEVH ranks highest on institutional and government (53rd percentile) and risk and compliance (46th), and lowest on insider conviction (1st), among Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
EVH filings, in plain words
Are Evolent Health insiders buying or selling EVH?
In the 180 days to 2026-10-27, Evolent Health insiders were net sellers, a net $329.5K across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of EVH?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $327.5K of stock; the latest, by Daniel McCarthy, was filed 2026-08-26.
Read the full summary
In the 180 days to 2026-10-27, Evolent Health insiders were net sellers of EVH, a net $329.5K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $327.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
